Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ContraFect Corp CFRXQ

Healthcare Biotechnology
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:CFRXQ)

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

GlobeNewswire October 16, 2023

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

GlobeNewswire September 19, 2023

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370

GlobeNewswire September 18, 2023

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

GlobeNewswire August 28, 2023

ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 14, 2023

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

GlobeNewswire June 27, 2023

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

GlobeNewswire June 20, 2023

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

GlobeNewswire June 8, 2023

ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 15, 2023
View More News ››

Opinion & Analysis (PINL:CFRXQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:CFRXQ)

CFRX..... You've all been had

Again Happy Fryday !
Iseneschal - April 28, 2023

CFRX....stopped out

Cheers !
Iseneschal - April 27, 2023

CFRX....expect the unexpected

This could pop..... $2.50 target My 1st entry here at $1.93 Fingers crossed....tight stop ; )
Iseneschal - April 27, 2023

CFRX..... N.L.O.D $2.03

What can I say ? I won't say it ; )
Iseneschal - April 27, 2023

CFRX.... Just when u think it's a sideways action

It breaks support and goes lower Leopards don't change spots  Neither do Maggots
Iseneschal - April 27, 2023

CFRX.... N.L.O.D $2.12

Playin possum Mr. M????
Iseneschal - April 27, 2023
View more Bullboard ››

Grid Battery Metals Inc.

Grid Battery Metals Inc.

Grid Battery Metals Inc. is a Canada-based exploration company. The Company focuses on exploration for high-value battery ...
View More »